Back to top
more

TESARO, Inc. (TSRO)

(Delayed Data from NSDQ)

$74.96 USD

74.96
NA

0.00 (0.00%)

Updated Jan 18, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

by Zacks Equity Research

TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

    Here's Why Clovis Stock Is Up Almost 60% So Far in 2017

    by Zacks Equity Research

    Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

      AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

      by Zacks Equity Research

      AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.

        Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

        by Zacks Equity Research

        Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

          What's in Store for Catalyst (CPRX) This Earnings Season?

          by Zacks Equity Research

          With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.

            Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?

            by Zacks Equity Research

            Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.

              Why Earnings Season Could Be Great for TESARO (TSRO)

              by Zacks Equity Research

              TESARO (TSRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                What's in Store for Intrexon (XON) in this Earnings Season?

                by Zacks Equity Research

                Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.

                  What to Expect from Epizyme (EPZM) This Earnings Season?

                  by Zacks Equity Research

                  Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.

                    Is a Beat in Store for Ionis (IONS) This Earnings Season?

                    by Zacks Equity Research

                    Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

                      Is Zoetis (ZTS) Poised for a Beat This Earnings Season?

                      by Zacks Equity Research

                      Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.

                        What's in the Cards for Endo (ENDP) this Earnings Season?

                        by Zacks Equity Research

                        Endo International plc (ENDP) remains focused on providing updates on its restructuring efforts across the Generics product as well as its manufacturing facility network in Q2.

                          What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?

                          by Zacks Equity Research

                          Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.

                            Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?

                            by Zacks Equity Research

                            Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2.

                              What's in Store for Agios Pharma (AGIO) in Q2 Earnings?

                              by Zacks Equity Research

                              Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.

                                What's in Store for Conatus (CNAT) this Earnings Season?

                                by Zacks Equity Research

                                Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.

                                  Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

                                  by Zacks Equity Research

                                  We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

                                    Is the Options Market Predicting a Spike in TESARO, Inc. (TSRO) Stock?

                                    by Zacks Equity Research

                                    Options Market is Predicting a Spike in TESARO, Inc. (TSRO) Stock on the back of its surging implied volatility.

                                      Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

                                      by Zacks Equity Research

                                      Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.

                                        Ryan McQueeney headshot

                                        Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today

                                        by Ryan McQueeney

                                        Shares of Clovis Oncology (CLVS) opened more than 40% higher on Monday morning after the company announced positive results in a late-stage trial involving its Rubraca therapy--an outcome that could help widen the use of the drug and give Clovis a competitive edge.

                                          Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

                                          by Zacks Equity Research

                                          Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

                                            Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                                            by Zacks Equity Research

                                            On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

                                              What Makes Tesaro (TSRO) a Strong Sell?

                                              by Zacks Equity Research

                                              Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                                                Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula

                                                by Zacks Equity Research

                                                TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.

                                                  Do Options Traders Know Something About Tesaro (TSRO) Stock We Don't?

                                                  by Zacks Equity Research

                                                  Options traders are pricing in a big move for Tesaro (TSRO) shares as it has huge implied volatility.